Archive for February, 2017

  • The Kidney Health Initiative

    KJC Statistics is proud to be part of the Kidney Health Initiative. The aim of the KHI is to “advance…

  • Risk managing your development with novel trial designs

    Novel, adaptive designs are seen by many drug developers as highly attractive as they seemingly offer more for less: more…

  • Why do so many phase III trials fail, despite promising phase II data?

    FDA reviews the learning from 22 case studies. Despite what are often reported as promising phase II data, the subsequent…

  • FDA guidance on non-inferiority trials

    As if justifying one wasn’t tough enough…now Sponsor have two non-inferiority margins to deal with?! Dealing with FDA’s new guidance…

  • KJC Statistics announces collaboration with ClaroStat Consulting

    KJC statistics is pleased to announce a working collaboration with Ms Claire Watkins, MSc, of ClaroStat Consulting. Claire has over…